Next Article in Journal
Pancreatic Cancer Cell-Derived Exosomes Promote Lymphangiogenesis by Downregulating ABHD11-AS1 Expression
Previous Article in Journal
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System
Previous Article in Special Issue
Classifying Germinal Center Derived Lymphomas—Navigate a Complex Transcriptional Landscape
 
 
Review

Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis

1
Center for Research and Drug Development (NPDM), Federal University of Ceara, Fortaleza 60020-181, Ceará, Brazil
2
Post-Graduate Program of Pathology, Federal University of Ceara, Fortaleza 60020-181, Ceará, Brazil
3
Post-Graduate Program in Translational Medicine, Federal University of Ceara, Fortaleza 60020-181, Ceará, Brazil
4
Post-Graduate Program in Medical Science, Federal University of Ceara, Fortaleza 60020-181, Ceará, Brazil
5
Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil
6
Boehringer Ingelheim Pharma GmbH & Co. KG, Pharmaceutical Development Biologicals, 88400 Biberach an der Riss, Germany
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Blanca Scheijen
Cancers 2022, 14(19), 4611; https://doi.org/10.3390/cancers14194611
Received: 3 June 2022 / Revised: 7 July 2022 / Accepted: 11 July 2022 / Published: 23 September 2022
(This article belongs to the Special Issue Molecular Characterization of Hematological Tumors)
The aging of the hematological system can cause physiological disorders such as anemia, reduced immunity, and the increased incidence of blood cancer. Patients diagnosed with hematologic malignancies comprise nearly 10% of all cancer deaths identified in international epidemiologic studies. Therefore, it is considered a public health problem worldwide. Scientific evidence demonstrates the important involvement of sirtuins (SIRTs) in the pathogenesis of several types of solid tumors. However, the role of SIRTs in the pathobiology of malignant hematological diseases has not yet been systematically reviewed. In this systematic review, we highlight the role of different SIRTs in the pathogenesis of acute and chronic leukemias, lymphoma and myeloma. Also, we performed a bioinformatic analysis to identify whether the expression of SIRTs is altered in onco-hematological diseases, such as lymphomas and leukemias. The advent of new applicability of SIRTs in the process of aging and hematological carcinogenesis may allow the development of new diagnostic and therapeutic approaches for these diseases.
The sirtuins (SIRT) gene family (SIRT1 to SIRT7) contains the targets implicated in cellular and organismal aging. The role of SIRTs expression in the pathogenesis and overall survival of patients diagnosed with solid tumors has been widely discussed. However, studies that seek to explain the role of these pathways in the hematopoietic aging process and the consequences of their instability in the pathogenesis of different onco-hematological diseases are still scarce. Therefore, we performed a systematic review (registered in PROSPERO database #CRD42022310079) and in silico analysis (based on GEPIA database) to discuss the role of SIRTs in the advancement of pathogenesis and/or prognosis for different hematological cancer types. In summary, given recent available scientific evidence and in silico gene expression analysis that supports the role of SIRTs in pathobiology of hematological malignances, such as leukemias, lymphomas and myeloma, it is clear the need for further high-quality research and clinical trials that expands the SIRT inhibition knowledge and its effect on controlling clonal progression caused by genomic instability characteristics of these diseases. Finally, SIRTs represent potential molecular targets in the control of the effects caused by aging on the failures of the hematopoietic system that can lead to the involvement of hematological neoplasms. View Full-Text
Keywords: sirtuins; onco-hematological disorders; aging biomarkers sirtuins; onco-hematological disorders; aging biomarkers
Show Figures

Figure 1

MDPI and ACS Style

Goes, J.V.C.; Carvalho, L.G.; de Oliveira, R.T.G.; Melo, M.M.d.L.; Novaes, L.A.C.; Moreno, D.A.; Gonçalves, P.G.; Montefusco-Pereira, C.V.; Pinheiro, R.F.; Ribeiro Junior, H.L. Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. Cancers 2022, 14, 4611. https://doi.org/10.3390/cancers14194611

AMA Style

Goes JVC, Carvalho LG, de Oliveira RTG, Melo MMdL, Novaes LAC, Moreno DA, Gonçalves PG, Montefusco-Pereira CV, Pinheiro RF, Ribeiro Junior HL. Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis. Cancers. 2022; 14(19):4611. https://doi.org/10.3390/cancers14194611

Chicago/Turabian Style

Goes, João Vitor Caetano, Luiz Gustavo Carvalho, Roberta Taiane Germano de Oliveira, Mayara Magna de Lima Melo, Lázaro Antônio Campanha Novaes, Daniel Antunes Moreno, Paola Gyuliane Gonçalves, Carlos Victor Montefusco-Pereira, Ronald Feitosa Pinheiro, and Howard Lopes Ribeiro Junior. 2022. "Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis" Cancers 14, no. 19: 4611. https://doi.org/10.3390/cancers14194611

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop